Imperial College London
Alternate

ProfessorFanChung

Faculty of Medicine, National Heart & Lung Institute

Professor of Respiratory Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 7954f.chung Website

 
 
//

Assistant

 

Miss Carolyn Green +44 (0)20 7594 7959

 
//

Location

 

227BGuy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kermani:2023:10.1080/17476348.2023.2278606,
author = {Kermani, N and Versi, A and Gay, A and Vlasma, J and Jayalatha, AKS and Koppelman, GH and Nawijn, M and Faiz, A and van, den Berge M and Adcock, IM and Chung, KF},
doi = {10.1080/17476348.2023.2278606},
journal = {Expert Review of Respiratory Medicine},
pages = {965--971},
title = {Gene signatures in U-BIOPRED severe asthma for molecular phenotyping and precision medicine: time for clinical use},
url = {http://dx.doi.org/10.1080/17476348.2023.2278606},
volume = {17},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: The use and generation of gene signatures have been established as a method to define molecular endotypes in complex diseases such as severe asthma. Bioinformatic approaches have now been applied to large omics datasets to define the various co-existing inflammatory and cellular functional pathways driving or characterizing a particular molecular endotype. AREAS COVERED: Molecular phenotypes and endotypes of Type 2 inflammatory pathways and also of non-Type 2 inflammatory pathways, such as IL-6 trans-signaling, IL-17 activation, and IL-22 activation, have been defined in the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes dataset. There has also been the identification of the role of mast cell activation and of macrophage dysfunction in various phenotypes of severe asthma. EXPERT OPINION: Phenotyping on the basis of clinical treatable traits is not sufficient for understanding of mechanisms driving the disease in severe asthma. It is time to consider whether certain patients with severe asthma, such as those non-responsive to current therapies, including Type 2 biologics, would be better served using an approach of molecular endotyping using gene signatures for management purposes rather than the current sole reliance on blood eosinophil counts or exhaled nitric oxide measurements.
AU  - Kermani,N
AU  - Versi,A
AU  - Gay,A
AU  - Vlasma,J
AU  - Jayalatha,AKS
AU  - Koppelman,GH
AU  - Nawijn,M
AU  - Faiz,A
AU  - van,den Berge M
AU  - Adcock,IM
AU  - Chung,KF
DO  - 10.1080/17476348.2023.2278606
EP  - 971
PY  - 2023///
SN  - 1747-6348
SP  - 965
TI  - Gene signatures in U-BIOPRED severe asthma for molecular phenotyping and precision medicine: time for clinical use
T2  - Expert Review of Respiratory Medicine
UR  - http://dx.doi.org/10.1080/17476348.2023.2278606
UR  - https://www.ncbi.nlm.nih.gov/pubmed/37997709
UR  - https://www.tandfonline.com/doi/full/10.1080/17476348.2023.2278606
UR  - http://hdl.handle.net/10044/1/108582
VL  - 17
ER  -
Download